Novel HIV Vaccine Generates Strong Broadly Neutralizing Antibody Responses in Preclinical Study

Researchers from La Jolla Institute for Immunology (LJI), Scripps Research, and IAVI have reported a major advance in HIV vaccine development, demonstrating an experimental vaccine strategy that produced unusually strong…

Continue Reading Novel HIV Vaccine Generates Strong Broadly Neutralizing Antibody Responses in Preclinical Study

CDC Endorses Twice-Yearly HIV Prevention Drug Yeztugo, But Access Barriers Remain

In a significant advancement for HIV prevention, the Centers for Disease Control and Prevention (CDC) has issued a strong recommendation for Yeztugo (lenacapavir), Gilead Sciences’ long-acting, twice-yearly pre-exposure prophylaxis (PrEP)…

Continue Reading CDC Endorses Twice-Yearly HIV Prevention Drug Yeztugo, But Access Barriers Remain